These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. Saponara M; Lolli C; Nannini M; DI Scioscio V; Serra C; Mandrioli A; Pallotti MC; Biasco G; Pantaleo MA Oncol Lett; 2014 Oct; 8(4):1793-1799. PubMed ID: 25202412 [TBL] [Abstract][Full Text] [Related]
65. Endocrine side effects of broad-acting kinase inhibitors. Lodish MB; Stratakis CA Endocr Relat Cancer; 2010 Sep; 17(3):R233-44. PubMed ID: 20603395 [TBL] [Abstract][Full Text] [Related]
66. A patient's perspective on the side effects of tyrosine kinase inhibitors in the treatment of advanced and metastatic gastrointestinal stromal tumors. van de Wal D; Venkatesan S; Benson C; van der Graaf WTA; Johnson CD; Husson O; Sodergren SC Future Oncol; 2023 Feb; 19(4):299-314. PubMed ID: 37038981 [TBL] [Abstract][Full Text] [Related]
67. Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature. van de Wal D; Elie M; Le Cesne A; Fumagalli E; den Hollander D; Jones RL; Marquina G; Steeghs N; van der Graaf WTA; Husson O Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406604 [TBL] [Abstract][Full Text] [Related]
68. Targeted therapy for cancer: asking the right questions. Schilsky RL Oncology (Williston Park); 2012 Oct; 26(10):947-9. PubMed ID: 23176006 [No Abstract] [Full Text] [Related]
72. THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors. Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Camastra S; Mazzi V; Miccoli M; Benvenga S; Antonelli A Eur J Endocrinol; 2021 Jan; 184(1):R29-R40. PubMed ID: 33112294 [TBL] [Abstract][Full Text] [Related]
73. A Rare Case of Sunitinib-Induced Exfoliative Esophagitis. Gayam S; Anumandla A ACG Case Rep J; 2016 Aug; 3(4):e155. PubMed ID: 27921054 [TBL] [Abstract][Full Text] [Related]
74. The side effects of imatinib. Uzer E; Unal A; Köker MY; Doğan SA Turk J Haematol; 2013 Sep; 30(3):341. PubMed ID: 24385822 [No Abstract] [Full Text] [Related]
75. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Caldemeyer L; Dugan M; Edwards J; Akard L Curr Hematol Malig Rep; 2016 Apr; 11(2):71-9. PubMed ID: 26922746 [TBL] [Abstract][Full Text] [Related]
76. [Phagotest and Bursttest (Phagoburst), test kits for study of phagocyte functions]. Hirt W; Nebe T; Birr C Wien Klin Wochenschr; 1994; 106(8):250-2. PubMed ID: 8023517 [TBL] [Abstract][Full Text] [Related]
77. Mechanism of fibronectin-mediated cell migration: dependence or independence of cell migration susceptibility on RGDS-directed receptor (integrin). Straus AH; Carter WG; Wayner EA; Hakomori S Exp Cell Res; 1989 Jul; 183(1):126-39. PubMed ID: 2544438 [TBL] [Abstract][Full Text] [Related]
79. A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients. Zeng L; Cheng X; Li J; Zhang J; Wu X PLoS One; 2024; 19(5):e0303290. PubMed ID: 38743680 [TBL] [Abstract][Full Text] [Related]
80. Psychological Distress, Fatigue and Quality of Life in Patients with Gastrointestinal Stromal Tumors. Carbajal-López EB; Juárez-García DM; Sánchez-Jauregui TJ; Espinoza-Velazco A; Calderillo-Ruiz G; Salas-Benavides R Psychol Russ; 2022; 15(2):3-13. PubMed ID: 36699707 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]